ArticleDiabetes, obesity & metabolism2026
The Risk of Disease Progression of Type 1 Diabetes in First-Degree Relatives of People With Type 1 Diabetes: Design and Rationale of a Prospective, Longitudinal Study in China.
Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
aimsIn China, information on individuals who test positive for islet autoantibodies (IAb), including single IAb-positive individuals and those with early-stage Type 1 diabetes (T1D), and their risk of progression to Stage 3 T1D is limited. The goal of this study is to assess the risk of progression to T1D in first-degree relatives (FDRs) of people with T1D in China. MATERIALS AND
methodsThis prospective, longitudinal study, being conducted at approximately 50 hospitals in China, will screen FDRs of individuals with T1D to identify those at risk for developing the disease by testing for the presence of IAb in the blood. IAb-positive individuals will undergo further testing for up to 5 years, with the primary objective of assessing their risk of Stage 3 T1D onset. During the monitoring period, participants with single IAb-positivity will be tested for glycated haemoglobin (HbA1c) and IAb every year; those with multiple IAb-positivity will have an HbA1c and oral glucose tolerance test (OGTT) every year (Stage 1 T1D), or OGTT or random blood glucose test in alternate 6-monthly intervals and HbA1c every 3 months (Stage 2 T1D). Participants who develop Stage 3 T1D during monitoring can undergo extended follow-up to assess changes in β-cell function, glycaemic outcomes and IAb status during the first 12 months after diagnosis. The study plans to enrol 5500 participants; enrolment is ongoing.
conclusionsThrough early screening and monitoring of disease progression in FDRs of T1D probands, this study will provide a comprehensive understanding of T1D progression in the Chinese population.
trial registrationChinese Clinical Trial Registry identifier: ChiCTR2600119032.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.